A B S T R A C T The immunogenicity and safety of two polysaccharides isolated from type III, group B Streptococcus, were tested in adults selected for existing low concentrations of natural antibody to the capsular polysaccharide of this organism. Both vaccine preparations (trichloroacetic acid and EDTA) were found to lack pyrogenicity and toxicity for experimental animals. A single 50-,ug subcutaneous injection of either polysaccharide in human subjects elicited significant increases in antibody concentration in immunized compared with control individuals receiving phosphate-buffered saline. Antibody responses were maximal by 2 wk and remained at 21 wk after immunization. Vaccine-induced antibody was primarily of the IgG class. Of the two vaccines, the larger molecular size polysaccharide was significantly more immunogenic. Although no systemic reactions were recorded, mild transient local reactions occurred in 45% of vaccinees.
INTRODUCTION
The importance of the group B Streptococcus as a cause of serious and often fatal infection among neonates and young infants is well established (1, 2) . Among isolates from these patients, -60% will be serologically classified as type III (3, 4 Diseases. Received for publication 3 January 1978. cytes and complement as determined by an opsonophagocytic assay (5). This same antibody has been detected by means of a quantitative radioactive antigen-binding assay in convalescent sera of' patients recovering from type III, group B streptococcal disease (6) . Our previous studies have shown a statistically significant correlation between risk for the development of invasive infant disease with type III strains and low concentration of maternal sertum anitibody to the type III capsular polysaccharide (6, 7) . The antibody directed against the capsular polysaccharide of type III strains is present in high concentration in the sera of many pregnant women, and is transplacentally transferred to the neonate in most circumstances (6, 7 (6, 7) . Sera were separated and stored in 2-ml aliquots at -70°C.
Results of the antibody responses to immunization were expressed as the geometric mean antibody concentration for each group (micrograms of antibody protein per milliliter of serum). 2 ml of selected subjects' sera collected at 2 and 8 wk after immunization with EDTA vaccine was fractionated and the immunoglobulins were purified (10). Statistical methods. The geometric mean antibody concentrations and 95% confidence intervals were calculated for each group of subjects (11) . Differences in the concentration of antibody in preimmunization and a 4-wk postimmunization sera for subjects in the EDTA and TCA vaccine groups compared to controls (PBS) and to each other were analyzed by the Wilcoxon rank sum test (12) Table I . No significant differences between the preimmunization concentrations of antibody were detected in sera from the three groups of volunteers. 2 and 4 wk after immunization with PBS, antibody concentration was unchanged in the sera from control subjects. However, 2 wk after the immunization, sera from TCAand EDTA-immunized volunteers had geometric mean antibody concentrations of 2.26 and 9.18 ,ug/ml, respectively. The rises in antibody concentration 4 wk after immunization with the EDTA and TCA vaccines were highly significant when compared to the PBS control group by means of the Wilcoxon rank sum text (P = <0.001) (12) . Furthermore, the EDTA vaccine was a significantly better immunogen than the TCA vaccine (P = <0.01).
To define the immunoglobulin class of vaccineinduced antibody, sera from selected vaccine recipients demonstrating high concentration of antibody in postimmunization sera were fractionated. IgG was found to be the immunoglobulin accounting for the majority of antigen-binding in sera from these selected vaccinees at 2 and 8 wk after immunization. That vaccine-induced antibody was primarily of the IgG class was further substantiated by the persistence of antibody in sera at similar concentrations 21 wk after immunization.
DISCUSSION
Infant disease due to group B Streptococcus is observed during the first 2-3 mo of life; the majority occurs at <7 days of age. This age is one during which transplacentally acquired maternal antibody, if present, protects young infants against a number of serious bacterial infections including disease due to type III, group B Streptococcus (6). Although polysaccharide vaccines have been shown to be relatively poor immunogens in infants, they are generally immunogenic in adults. Therefore, immunization of women with polysaccharides from group B Streptococcus offers the theoretical advantage of preventing disease in neonates and young infants by transplacental passage of antibody.
We have assessed the safety and antigenicity of two relatively large molecular size polysaccharides extracted by different methods from a type III strain of group B Streptococcus. One polysaccharide was extracted by washing cells grown in Todd-Hewitt broth supplemented with glucose with neutral buffer-EDTA solution. After purification, this EDTA-III polysaccharide had a molecular size of 600,000 daltons. The second polysaccharide (TCA-III) was isolated from EDTA-washed cells by extraction with cold 10% TCA, and after purification it had a molecular size of 500,000 daltons. Both preparations were nontoxic in laboratory animals, and no untoward systemic reactions were observed in human volunteers. Local reactions were detected primarily in the EDTA vaccinees. These were mild, of short duration, and were similar to those which have been reported for several other bacterial polysaccharide vaccines.
The EDTA-III polysaccharide possessed significantly greater immunogenicity than the TCA-III vaccine as indicated by the number of subjects responding to immunization and the magnitude oftheir antibody response. This greater immunogenicity may be a reflection of the larger molecular size of the EDTA preparation. Size has been shown to be a crucial determinant of the immunogenicity of polysaccharides (15) and pneumococcal polysaccharides (16) in adtults when response for subjects with low levels of antibody in preimmunization sera are analyzed separately. Since women with low concentrations of serum antibody to the capsular polysaceharide from type III, group B Streptococcus are those whose offspring are at risk for disease due to this mieroorgainism (6, 7) , the potential uisefulness of' an effective immunogen in this poptilationi requires evaluation. Althouigh further studies are nee(led, the demonistrationi of the safety and immutnogenicity of' the EDTA-III polysaccharide in mian represents the first step in realizing the prevention of' grouip B streptococcal disease in neoniates and young inftants by immuntiologic menthodIs.
